AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01541488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 1021958
Description: SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
Study NCT02151656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F17464
Study NCT02151656 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00087984 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MB-002
Description: Dendritic Cell Immunotherapy
Study NCT02709720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
Study NCT02709720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 1 and 2 day 1, 80 mg/m2
Study NCT02709720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
Study NCT02709720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cycle 3 and 4 day 1, 80 mg/m2
Study NCT02709720 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: concomitant therapy during cycles 3 and 4. Total dose: 66Gy
Study NCT02615119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoproterenol
Description: Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
Study NCT02615119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoproterenol
Description: Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
Study NCT02615119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
Study NCT02615119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
Study NCT00972517 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Three intramuscular injections
Study NCT04105959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIST4721
Description: RIST4721 oral solution
Study NCT04105959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral solution
Study NCT01152801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Study NCT02446821 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeraCept
Description: IUD placement of VeraCept
Study NCT02199093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Rehabilitation of apraxia
Description: The intervention will cover every type of approaches related with upper limb apraxia.~We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.~On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence.
Study NCT02199093 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional health educative protocol
Description: The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
Study NCT01102491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
Study NCT05532228 — intervention group
Intervention type: PROCEDURE
Intervention: Adenotonsillectomy
Description: adenotonsillectomy by cold dissection
Study NCT05762042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dietary supplement
Description: Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally.
Study NCT05762042 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary supplement
Description: Femal, a food supplement based on pollen extracts introduced in Europe in 1999, is a non-estrogenic alternative to hormone replacement therapy in women with vasomotor symptoms.~The mechanism of action of Femal has not yet been fully clarified: Femal inhibits the absorption of serotonin in a dose-dependent manner and has strong antioxidant properties.~The lack of estrogenic effects would make this preparation of particular interest for women with a previous hormone-dependent neoplasia who undergo an early iatrogenic menopause.~Femal tablets contain a standardized formulation containing: GC Fem pollen extract 40 mg, PI82 pollen / pistil extract 120 mg, vitamin E 5 mg, amino acids 14 mg per tablet.~The dosage is 2 tablets a day orally.
Study NCT01010451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Antimicrobial pulpotomy
Description: Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
Study NCT01010451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide pulpectomy
Description: Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
Study NCT02953561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV
Study NCT02953561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT02953561 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01791621 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elimination/Challenge Diet
Description: An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.~The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team.
Study NCT00731861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus PTK787
Description: Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.~In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY.
Study NCT02013349 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: coronary intervention
Study NCT01148693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Distilled water
Study NCT03485222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 6 months
Study NCT02834650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI without contrast
Description: Cardiac MRI
Study NCT02834650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Test
Description: Hematocrit, Creatinine, Troponin, BNP
Study NCT01179269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib plus Paclitaxel
Description: Pazopanib daily and weekly paclitaxel IV
Study NCT02834650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Rate
Description: Holter Monitor
Study NCT02298309 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Test-and-Treat TB
Study NCT02834650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Test
Description: Pulmonary Function Test
Study NCT04310319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Sodiumchloride
Description: Subjects will receive 4 capsules containting 750 NaCl each 2dd, making a total of 6 grams NaCl per day.
Study NCT04310319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Protein
Description: Subjects will receive 2dd 40 ml of a protein beverage containing 0.5 grams of protein per ml, making a total of 40 grams of protein per day.
Study NCT02834650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Genetic Testing
Study NCT02834650 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeat MRI scan
Description: Repeat MRI scan
Study NCT01914627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethicone
Description: The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
Study NCT03485222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo equivalent for 6 months
Study NCT01914627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salicylic Acid
Description: The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
Study NCT04310319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo comparator (salt)
Description: Subjects will receive 4 placebo capsules (identical to salt capsules) 2dd.
Study NCT04310319 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo comparator (protein)
Description: Subjects will receive 2dd 40 ml of placebo beverage (identical to protein beverage).
Study NCT02006108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Feraheme
Description: Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
Study NCT02006108 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI-GE Healthcare 3 Tesla magnet
Description: All patients will undergo
Study NCT03015155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of Cold Saline into Local Infarction Myocardium.
Description: Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
Study NCT03948893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement (MORE)
Description: MORE is a behavioral therapy that integrates mindfulness training to modify reward processes.
Study NCT03948893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: CBT is a therapy designed to help individuals understand how their thoughts and feelings influence their behaviors.
Study NCT00550186 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00550186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringers Lactate
Study NCT00550186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HaemoHES 6%
Study NCT01412125 — intervention group
Intervention type: OTHER
Intervention: Huntington patient evaluation
Description: Neurological, neuropsychological, neuroimaging evaluation and biological sample
Study NCT01412125 — intervention group
Intervention type: OTHER
Intervention: Healthy subject evaluation
Description: Neurological, neuropsychological, neuroimaging evaluation and biological sample
Study NCT04556526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV
Description: Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
Study NCT04556526 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Ad26.ZEBOV
Description: Participants in Group A will receive 0.5 mL IM injection of Ad26.ZEBOV vaccine. Participants in Group B will receive Ad26.ZEBOV 6 weeks after delivery/termination of pregnancy.
Study NCT04556526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-Filo
Description: Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
Study NCT04556526 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MVA-BN-Filo
Description: Participants in Group A will receive 0.5 mL IM injection of MVA-BN-Filo vaccine. Participants in Group B will receive MVA-BN-Filo 6 weeks after delivery/termination of pregnancy.
Study NCT02906410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Item-Level Calorie information
Description: Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
Study NCT02906410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal-Level Calorie information
Description: Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen.
Study NCT04152954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation of cervical medial branches
Description: Radiofrequency ablation of cervical medial branches
Study NCT04152954 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation of cervical medial branches
Description: Radiofrequency ablation of cervical medial branches
Study NCT01492426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Film-coated tablet, oral, 60 mg, once daily, 24 weeks
Study NCT01492426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Film-coated tablet, oral, 750 mg, 3 times daily
Study NCT01492426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Solution for injection, subcutaneous injection, 180 μg, weekly
Study NCT01492426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
Study NCT04453826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemo-radiotherapy
Description: 1. Camrelizumab: 200 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of camrelizumab are concurrently used during radiotherapy and camrelizumab are maintained for 1 year after the end of radiotherapy.~2. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~3. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~4. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
Study NCT04453826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemo-radiotherapy alone
Description: 1. Gemcitabine plus cisplatin induction chemotherapy: gemcitabine is injected intravenously at the dose of 1000 mg/m2 on the 1st and 8th day (within 30 minutes) for 3 cycles; cisplatin is injected intravenously at the dose of 80 mg/m2 on the 1st day, for 3 cycles. 1 cycles per 3 weeks.~2. Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.~3. IMRT: PTVnx#69.96Gy/33Fr/2.12Gy; PTVnd#69.96Gy/33Fr/2.12Gy; PTV1#59.4Gy/33Fr/1.8Gy; PTV2#54Gy/33Fr/1.64Gy
Study NCT02610972 — intervention group
Intervention type: DEVICE
Intervention: Congo Red test GV-005
Description: Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
Study NCT04584398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training with steam inhalation
Study NCT03961555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SYN023
Description: it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
Study NCT03961555 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HRIG (HyperRab)
Description: it is administered by direct injection into the wound or by subcutaneous or intramuscular injection when this is not possible
Study NCT03961555 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: it should be administered in deltoid muscle
Study NCT03961555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: it should be administered in deltoid muscle
Study NCT04525144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebonin Forte
Description: Dietary supplement: Gingko biloba EGb 761
Study NCT01715389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyAsthma Patient Portal
Description: Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.~Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms.
Study NCT01170273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: cholecalciferol
Study NCT01170273 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablet
Study NCT02374060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Periocular triamcinolone 40 mg
Description: Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
Study NCT02374060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal triamcinolone 4 mg
Description: Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
Study NCT02374060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone intravitreal implant
Description: • Standard preparation as described for intravitreal injections.
Study NCT02094118 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Point-of-care washed red blood cell transfusion.
Study NCT02094118 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care red blood cell transfusion.
Study NCT04509570 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: 5\~20mg/ml, intralesional injection every 1 month. Number of cycles: until the lesions are clinically cleared
Study NCT01121055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam
Description: Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
Study NCT01121055 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
Study NCT02549989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
Study NCT02954224 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3